Salina Gin-Schuan Yuan, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Histone-Lysine N-Methyltransferase | 1 | 2020 | 674 | 0.520 |
Why?
|
| Neoplastic Stem Cells | 2 | 2019 | 1343 | 0.440 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2024 | 725 | 0.390 |
Why?
|
| Histones | 2 | 2020 | 2552 | 0.360 |
Why?
|
| Pancreatic Neoplasms | 7 | 2024 | 5260 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2020 | 8356 | 0.310 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2024 | 1672 | 0.280 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2020 | 1060 | 0.250 |
Why?
|
| Tumor Microenvironment | 6 | 2024 | 3695 | 0.230 |
Why?
|
| Neoplasms | 2 | 2020 | 21715 | 0.180 |
Why?
|
| bcl-X Protein | 1 | 2022 | 421 | 0.180 |
Why?
|
| Metaplasia | 1 | 2019 | 322 | 0.150 |
Why?
|
| ATP Citrate (pro-S)-Lyase | 1 | 2017 | 22 | 0.150 |
Why?
|
| Acetyl Coenzyme A | 1 | 2017 | 74 | 0.150 |
Why?
|
| Lymphocyte Subsets | 1 | 2018 | 310 | 0.140 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2019 | 454 | 0.140 |
Why?
|
| Oncogenes | 1 | 2022 | 1216 | 0.130 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2017 | 584 | 0.110 |
Why?
|
| Mammary Glands, Animal | 1 | 2014 | 264 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 1801 | 0.100 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 3654 | 0.090 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 1131 | 0.090 |
Why?
|
| Cell Line, Tumor | 6 | 2024 | 16667 | 0.090 |
Why?
|
| Immunologic Factors | 1 | 2018 | 1567 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2017 | 2898 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 1598 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2024 | 4593 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 3541 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2018 | 3667 | 0.070 |
Why?
|
| Nuclear Proteins | 2 | 2022 | 5748 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 2803 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 5166 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2019 | 10311 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 6300 | 0.050 |
Why?
|
| Histone Acetyltransferases | 1 | 2022 | 331 | 0.040 |
Why?
|
| Animals | 7 | 2020 | 166558 | 0.040 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2020 | 169 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 6142 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2019 | 23154 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2018 | 3585 | 0.040 |
Why?
|
| Transfection | 2 | 2017 | 5789 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2014 | 7786 | 0.040 |
Why?
|
| Humans | 12 | 2024 | 746630 | 0.040 |
Why?
|
| Albumins | 1 | 2019 | 563 | 0.040 |
Why?
|
| RNA Interference | 2 | 2017 | 2845 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 788 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2017 | 400 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2019 | 845 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 1408 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 1690 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 21600 | 0.030 |
Why?
|
| Apoptosis | 2 | 2022 | 9447 | 0.030 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2014 | 41 | 0.030 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2014 | 58 | 0.030 |
Why?
|
| Mice | 5 | 2020 | 80251 | 0.030 |
Why?
|
| Acetylation | 1 | 2017 | 1047 | 0.030 |
Why?
|
| Immunity | 1 | 2020 | 993 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 2017 | 560 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2022 | 2922 | 0.030 |
Why?
|
| Protein Binding | 2 | 2017 | 9284 | 0.030 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2014 | 160 | 0.030 |
Why?
|
| Cadherins | 1 | 2018 | 903 | 0.030 |
Why?
|
| Serine | 1 | 2017 | 823 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2017 | 687 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 2014 | 527 | 0.030 |
Why?
|
| Epigenomics | 1 | 2018 | 911 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2019 | 1693 | 0.030 |
Why?
|
| Endonucleases | 1 | 2014 | 369 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2019 | 3143 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2017 | 3081 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2019 | 2170 | 0.020 |
Why?
|
| Oxygen | 1 | 2022 | 4182 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2022 | 12044 | 0.020 |
Why?
|
| Chromatin | 1 | 2022 | 2896 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2022 | 3611 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2017 | 1951 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8521 | 0.020 |
Why?
|
| Mutation | 2 | 2023 | 29627 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 20763 | 0.020 |
Why?
|
| Cell Movement | 1 | 2018 | 5166 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2017 | 8294 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 9193 | 0.020 |
Why?
|
| Glucose | 1 | 2017 | 4304 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 1886 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 4182 | 0.020 |
Why?
|
| Genomics | 1 | 2020 | 5695 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 4516 | 0.020 |
Why?
|
| Time Factors | 2 | 2017 | 39622 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 10018 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 9320 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 9513 | 0.010 |
Why?
|
| Prognosis | 1 | 2020 | 29079 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2014 | 14253 | 0.010 |
Why?
|
| Female | 4 | 2019 | 382450 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 16261 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 13218 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 63732 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 57586 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 17445 | 0.010 |
Why?
|
| Aged | 1 | 2018 | 164383 | 0.000 |
Why?
|
| Middle Aged | 1 | 2018 | 214618 | 0.000 |
Why?
|
| Male | 1 | 2018 | 351420 | 0.000 |
Why?
|